Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Myovant Sciences Ltd.

http://myovant.com/

Latest From Myovant Sciences Ltd.

Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product

Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.

Gynecology & Urology Clinical Trials

Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Cancer

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Approvals Neurology

Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?

Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
  • Other Names / Subsidiaries
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
UsernamePublicRestriction

Register